22:44 , Apr 10, 2018 |  BC Innovations  |  Distillery Techniques

Drug delivery

TECHNOLOGY: Nanoparticles Nanoparticles based on EIF2AK2 could be used to deliver siRNAs to treat cancer and other diseases. The nanoparticles consist of a polyethylene glycol (PEG) core linked to a histidine-rich peptide for enhanced cellular...
00:28 , Mar 31, 2017 |  BC Innovations  |  Targets & Mechanisms

Cells on the rise

This year’s meeting of the American Association for Cancer Research (AACR) will keep the spotlight on immuno-oncology, where preclinical science is continuing to expand the use of different types of innate and adaptive immune cells...
07:00 , Sep 23, 2010 |  BC Innovations  |  Distillery Techniques

Technology: Drug platforms

Approach Summary Licensing status Publication and contact information Drug platforms Killing cancer cells using small conditional RNAs A study in cell culture suggests that self-assembling RNA duplexes could be used to kill tumor cells. In...
07:00 , Sep 4, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cancer Cancer Caspase-12; eukaryotic translation initiation factor 2, subunit 1a (EIF2S1; EIF2a); protein kinase regulated by RNA (PKR) Studies in cell...
07:00 , Oct 8, 2007 |  BC Week In Review  |  Clinical News

Introgen preclinical data

In vitro, INGN 241 plus Velcade bortezomib killed ovarian cancer cells. Data were published in Cancer Gene Therapy. INGN 241 is a modified adenoviral vector encoding the MDA-7 tumor suppressor gene that interacts with protein...
08:00 , Jan 29, 2007 |  BC Week In Review  |  Clinical News

Introgen preclinical data

Researchers published in Molecular Therapy that in a mouse model of NSCLC, INGN 241 plus Avastin significantly inhibited tumor growth vs. either agent alone (p<0.05). The combination led to complete tumor regression in all mice...
08:00 , Jan 15, 2007 |  BC Week In Review  |  Clinical News

Introgen preclinical data

Researchers published in Cancer Gene Therapy that INGN 241 in combination with 2 Hsp90 inhibitors, gldanamycin or 17-AAG, had a synergistic effect in increasing cell death in lung cancer cells. The combinations also inhibited tumor...
07:00 , Apr 10, 2006 |  BC Week In Review  |  Clinical News

Introgen preclinical data

In a mouse model of human lung cancer, INGN-241 plus Avastin led to about 70% complete tumor regression, resulting in significantly improved survival vs. either agent alone or controls. Data were presented at the American...
08:00 , Nov 14, 2005 |  BC Week In Review  |  Clinical News

Introgen preclinical data

Researchers published in Surgery that INGN 241 plus Celebrex significantly increased cell death in breast cancer cells compared to either montherapy alone (p<0.05) and led to apoptosis and cell cycle block. INGN 241 is a...
08:00 , Nov 7, 2005 |  BC Week In Review  |  Clinical News

Introgen preclinical data

Researchers published in Molecular Therapy that, in human prostate cancer cell lines, INGN 241 significantly inhibited VEGF expression (p<0.05). INGN 241 is a modified adenoviral vector encoding the MDA-7/IL-24 tumor suppressor gene which interacts with...